Comparative Pharmacology
Head-to-head clinical analysis: ARISTOGEL versus DECADRON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARISTOGEL versus DECADRON.
ARISTOGEL vs DECADRON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Testosterone replacement therapy; binds to androgen receptors, activating gene transcription and increasing protein synthesis.
Dexamethasone is a glucocorticoid receptor agonist, binding to the glucocorticoid receptor and modulating gene expression to produce anti-inflammatory and immunosuppressive effects. It also suppresses adrenal function by inhibiting ACTH secretion.
Aristogel is a topical gel containing 1% testosterone. The recommended adult dose is 5 g (50 mg testosterone) applied once daily to clean, dry, intact skin of shoulders, upper arms, and/or abdomen. Apply at approximately the same time each day, preferably in the morning.
0.75-9 mg/day orally in divided doses every 6-12 hours; or 0.5-9 mg/day IM/IV in divided doses every 12 hours for acute conditions; for cerebral edema, IV loading dose of 10 mg followed by 4 mg IM/IV every 6 hours.
None Documented
None Documented
Terminal elimination half-life is 12 hours. Given dosing frequency, steady-state achieved within 2 days; accumulation minimal with standard dosing.
Terminal half-life: 3-4 hours (plasma); biological half-life: 36-54 hours (due to intracellular receptor binding); clinical context: duration of HPA axis suppression longer than plasma half-life
Primarily renal (80%) as unchanged drug; 20% fecal via biliary elimination.
Renal (65-80% as 17-hydroxycorticosteroids and 20-hydroxycorticosteroids after hepatic metabolism); biliary/fecal (minor, <10%)
Category C
Category C
Corticosteroid
Corticosteroid